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Across the globe, over 200 million annual malaria
infections result in up to 660,000 deaths, 77% of which
occur in children under the age of five years. Although
prevention is important, malaria deaths are typically
prevented by using antimalarial drugs that eliminate
symptoms and clear parasites from the blood.
Artemisinins are one of the few remaining compound
classes that can be used to cure multidrug-resistant
Plasmodium falciparum infections. Unfortunately,
clinical trials from Southeast Asia are showing that
artemisinin-based treatments are beginning to lose
their effectiveness, adding renewed urgency to the
search for the genetic determinants of parasite
resistance to this important drug class. We review
the genetic and genomic approaches that have led
to an improved understanding of artemisinin resistance,
including the identification of resistance-conferring
mutations in the P. falciparum kelch13 gene.those able to cure mice and monkeys that had rodent and
simian malaria, respectively (reviewed in [5,6]). ArtemisininIntroduction
Malaria, classically identified by paroxysm, fever, and
flu-like symptoms recurring in 48- or 72-hour cycles, is
caused by protozoan parasites of the genus Plasmodium
and is transmitted by the bite of female Anopheles mos-
quitoes (Figure 1). The species causing the most severe
form of the disease is Plasmodium falciparum (Box 1).
Although insecticide-treated bed nets, and other pre-
ventive measures are important in the control of
malaria, in the absence of a licensed vaccine and ac-
quired, fully-protective immunity, chemotherapy has
been and continues to be one of the best ways to prevent
deaths, to control symptoms, and to eliminate parasites
from a given geographic region. A recurrent problem
with chemotherapy is that parasites, like other microbes,* Correspondence: ewinzeler@ucsd.edu
School of Medicine, University of California San Diego, Gilman Drive, La Jolla,
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unless otherwise stated.can and will rapidly evolve mechanisms to escape drug
pressure and survive. Although arguably augmented by
other factors, such as reduced spending on malaria con-
trol, the emergence and spread of multidrug-resistant P.
falciparum parasites has probably contributed, directly
or indirectly, to hundreds of millions of new cases each
year and to millions of unnecessary deaths between 1970
and 2000 [1-3].
The introduction of a new antimalarial treatment has
been soon followed by the emergence of resistance to that
treatment; perhaps most notably, parasites resistant to the
antimalarial atovaquone were discovered the same year the
drug was introduced [4]. After P. falciparum parasites be-
came resistant to chloroquine, pyrimethamine/sulfadoxine,
mefloquine and then atovaquone, P. falciparum malaria
became very difficult to cure. Thus, the world enthusiastic-
ally welcomed the appearance of a new class of medicines
based on extracts from the sweet wormwood plant,
Artemisia annua. The antimalarial activity of A. annua had
been rediscovered in a screen of traditional medicines for
derivatives (Figure 2) are typically combined with a partner
drug, typically from a chemical family such as the aryl alco-
hols or 4-aminoquinolones, to comprise artemisinin-based
combination therapies (ACTs). Indeed, the World Health
Organization only supports the use of artemisinins in com-
binations, reasoning that this will delay the appearance of
drug resistance because a parasite will need to acquire re-
sistance to two drugs as opposed to just one. Although not
recommended for use everywhere, ACTs are currently
considered the most effective treatments for P. falciparum
malaria in areas where drug resistance to other therapies
has been a problem. Nevertheless, clinical trials from
Southeast Asia indicate parasites have now acquired resist-
ance to artemisinin-based monotherapies and some ACTs
appear to be losing effectiveness [7]. Although no deaths
can be directly attributed to resistance, further reductions
in ACT efficacy could result in malaria again becoming a
possibly incurable and often fatal disease.Central Ltd. The licensee has exclusive rights to distribute this article, in any
ion. After this time, the article is available under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Figure 1 The lifecycle of Plasmodium that begins with the bite of a female Anophelesmosquito which releases infective sporozoites into the
blood of the host. The sporozoites travel to the liver and invade liver cells. Within the liver the sporozoites mature into schizonts, which subsequently grow
and produce haploid forms called merozoites. In P. vivax, these liver forms can remain dormant for years as hypnozoites and cause relapse of infection.
Merozoites re-enter the bloodstream and invade red blood cells and undergo a cycle of asexual multiplication (A); however, some of the merozoites develop
into sexual forms called gametocytes, which circulate in the bloodstream, and can be ingested by a mosquito, thus continuing the malaria lifecycle (B). Drug
efficacy can be monitored by collecting blood samples in a treated patient and counting the number of infected erythrocytes using microscopy, or the
parasites can be taken into long-term or short-term tissue culture, and these cultured parasites can be mixed with a drug at different concentrations and their
in vitro survival or growth monitored [51]. The grey arrows depict the progression of the Plasmodium lifecycle and the black arrows indicate lifecycle forms.
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Box 1. Challenges to working with malaria parasites:
a complex lifecycle and logistical barriers
Malaria parasites have a complex lifecycle (Figure 1). Although the
parasite replicates asexually as a haploid organism in human and
mosquito tissues, it has a sexual cycle with meiosis and a brief
diploid phase, which occurs in the mosquito. The sexual
re-assortment that occurs within mosquitoes is the basis for the
genome-wide association studies of parasites in humans. Sexual
crosses between resistant and sensitive parasites can be performed
for P. falciparum and have been used to map drug-resistance genes
in the past [70,71], but the method is not particularly accessible. Few
researchers have access to all stages of the complex lifecycle, which
is needed to complete genetic crosses. Although there are rodent
models of malaria, which in some cases (such as Plasmodium
chabaudi, Plasmodium berghei, and Plasmodium yoelii) can be more
readily used in forward and reverse genetics, other human malaria
parasites, such as Plasmodium vivax, cannot even be cultured
long-term.
P. falciparum has an approximately 24 megabase haploid genome,
notable for its extreme AT-richness [72]. Although malaria has been
and continues to be a strong selective force on the human
genome, the function of many of the predicted approximately
5,300 proteins encoded by the parasite genome can only be
inferred from studies of orthologs in model organisms. A notable
feature is that the genome bears long tracts of repetitive,
recombinogenic sequence that may assist with immune evasion,
but which makes genome manipulation and cloning challenging.
Some of these recombinogenic tracts are within multigene families,
some are intergenic, and some are within genes. For example, the
amino terminus of PfKelch13 is predicted to have the low
complexity protein coding sequence ‘NNNINHNNNNNNLTANNITNN
LINNNMN’ within its first 200 amino acids (Figure 1). In vitro
evolution studies have shown that repetitive sequences are more
prone to mitotic gene conversion than sequences that do not
contain repetitive sequences [73], but they are also more difficult to
sequence and study. Outside of repetitive regions, the rate of
mutation is probably similar to those found in other organisms [73].
Although the blood stages of P. falciparum can be maintained
in cell culture using human erythrocytes obtained from donors,
parasites cannot be as readily taken into cell culture for drug
sensitivity testing. Furthermore, given that the disease can
rapidly turn fatal, treatment recommendations may be made on
the basis of the number of parasites that are PCR positive for a
resistance marker in a region. The patient parasite clearance
studies (Figure 1) in which parasite numbers are counted by
simple light microscopy involve consented clinical trials in
which patients agreed to be treated with a monotherapy
(versus an ACT) initially but are closely monitored and then
treated with a second drug or ACT. Although simple in design,
these studies are relatively costly and are influenced by host
factors, including a person’s immunity or whether the person
has alleles that protect against malaria, such as the sickle cell allele,
HbS. Individuals with this allele could theoretically clear parasites
more quickly than those without. In vitro drug-sensitivity assays, in
which parasites are incubated in the presence of increasing drug
concentrations (to obtain an EC50), are more quantifiable (Figure 1)
but may require more specialized laboratory equipment, such as
incubators and tissue culture facilities. For artemisinin-resistance
studies, a modified RSA in which parasites are first synchronized
is typically used [51]. Genotyping parasites that have been
phenotyped by both types of tests may be complicated by
multiclone infections.
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arial compounds [8-10] to replace artemisinin are cur-
rently underway, but no new drugs are expected to be
licensed within the next few years. In the absence of a
forthcoming replacement medicine, concerned physi-
cians, scientists, and government officials have been
working diligently to try to find parasite genetic markers
that predict artemisinin resistance. Such markers will
facilitate tracking of the spread of resistance and hopefully
will allow resistance to be contained before early-stage
treatment failures and possible deaths result. Importantly,
having a genetic marker could also prevent deaths: if sur-
veillance identifies the widespread presence of resistance-
associated alleles in a given geographic region, patients in
those regions might be admitted to a hospital for closer
observation during treatment or given alternative therap-
ies. In this review, we describe the genomic detective work
that has been used to find the genes involved in artemisi-
nin resistance, the emerging evidence that mutations in a
gene encoding a Kelch-propeller domain protein confers
resistance in P. falciparum malaria, alternative hypotheses,
and the open questions that remain.
Hypotheses about artemisinin’s function and its
possible association with resistance
A logical place to look for genes that are involved in resist-
ance to a particular drug would be in the molecular path-
ways associated with the target. For example, resistance to
antifolate drugs is often caused by mutations in proteins in
the folate biosynthesis pathway. Surprisingly, even though
331 million courses of various ACT treatments were given
in 2013 [2], the mechanisms by which artemisinins act is
still the subject of intensive investigation (Box 2; reviewed
in [11]). In 2003, it was reported that artemisinin targets
the P. falciparum homolog of the sarcoplasmic reticulum
Box 2. Artemisinins, their use and chemical
background
There are a number of different artemisinin derivatives with
antimalarial activities, including artesunate, dihydroartemisinin,
and artemether (reviewed in [11]; Figure 2). Artemisinins are
sesquiterpene lactones with a 1,2,4-trioxane core incorporating
an endoperoxide linkage. Structure-activity relationship studies
have shown that the active part of the molecule is the unusual
endoperoxide bridge, and those synthetic molecules (for example,
OZ439 and arterolane) that also bear this endoperoxide bridge are
also very potent antimalarials [74]. There is substantial evidence
that artemisinins form free radicals that attack various parasite
proteins [75]. Parasites appear most susceptible to endoperoxides
in the early ring stages of the parasite life cycle [68]. In fact,
endoperoxides have reduced activity against stages of the life
cycle during which hemoglobin digestion is not occurring, such as
the hepatic stages [76], suggesting that hemoglobin digestion and
the release of iron play a role in the action of the endoperoxide
class. Indeed, inhibition of hemoglobinase activity with cysteine
protease inhibitors, knockout of the cysteine protease pffalcipain-2
by gene deletion, or direct deprivation of host cell lysate all
significantly decrease the artemisinin sensitivity of P. falciparum [68].
Artemisinins are used in combination with partner compounds
to prevent the development of resistance. Artesunate with
amodiaquine, artesunate with mefloquine, artemether with
lumefantrine, dihydroartemisinin with piperaquine, and
artesunate with pyronaridine comprise what are generically
known as ACTs. Although these are expensive relative to drugs
composed of only older synthetic compounds such as
chloroquine, they are nevertheless considered the gold standard
for treating uncomplicated P. falciparum malaria because of their
efficacy against multi-drug-resistant malaria and their rapid
speed of action [77].
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hypothesis was based on evidence that artemisinin de-
creased ATPase activity in Xenopus oocytes expressing
PfATP6 with similar potency to thapsigargin, another
SERCA inhibitor. The hypothesis was subject to substantial
investigation, but no further association between pfatp6
mutations and artemisinin could be firmly established
[13-16]. Importantly, several years later, it was eventually
shown that, when compared with isogenic controls, no
novel pfatp6 mutations were present in Asian P. falciparum
parasites that had acquired resistance to artemisinin [17],
nor were there mutations in rodent malaria parasites that
were resistant to artemisinin and artesunate [16].Known multidrug-resistance genes
Some of the original studies seeking to find genes that
are involved in artemisinin resistance were based on the
hypothesis that known transporter-encoding genes,
including pfmdr1 [18,19], encoding the P. falciparum
Multidrug resistant protein 1 (PfMDR1), and pfcrt [20],
encoding the P. falciparum Chloroquine resistance
transporter (PfCRT), would contribute to resistance.
Some evidence has been encouraging: decreasing the
number of copies of the gene encoding PfMDR1 resulted
in increased sensitivity to artemisinin [21]. Mutations in
pfmdr1 have also been shown to modulate inhibition
constant 50 (IC50) values for artemisinin in vitro [22].
Furthermore, field studies revealed an overrepresenta-
tion of the pfmdr1 I876V mutation in parasites causing
recurrent infections after artemether-lumefantrine treat-
ment in Africa [23]. Prevalent mutant forms of pfcrt
that confer chloroquine resistance have been shown to
increase parasite susceptibility to artemisinin, and epi-
demiological studies have shown selection for wild-type
pfcrt in endemic settings where ACTs are used [24,25].
Despite frequent reports of possible associations, the
genotyping of parasites in Cambodia, where artemisinin
resistance now appears most widespread and where
monotherapies were used, have indicated that specific
coding changes in these candidate genes as well as in
pfatp6 and pfubp1 are not strongly correlated with re-
sistance [26]. On the other hand, many of these assays
looked for single nucleotide variants (SNVs) in the gene
and may not have detected an increase in copy number.
The lack of disease association with specific genes in
Asia does not necessarily mean that these genes do not
contribute to resistance or give a different resistance
phenotype.
Evolution studies
In other microbial systems, genes that are involved in re-
sistance have been identified by first creating resistant
mutants and then mapping the genes that confer resist-
ance. Such an approach would be attractive except that
crosses in P. falciparum have required the use of chim-
panzees, in which progeny parasites are grown and
cloned after they emerge from the liver after a genetic
cross. Plasmodium chabaudi rodent parasites can be
genetically crossed more readily in the laboratory (Box
1), and hence researchers were able to create P. cha-
baudi rodent parasites that were resistant to artemisinin
and artesunate by continuing exposure to sublethal con-
centrations of these compounds [16,27]. They then
crossed the ART resistant line to another sensitive line
of parasites that differed from the original at many gen-
etic positions. Instead of cloning out and genotyping the
recombinant progeny lines, selection was applied in bulk
and the relative proportion of different markers for each
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Figure 2 Chemical structures of commonly used antimalarials, including artemisinin, artesunate, artemether and OZ439. The chemistry
of artemisinins is described in detail in Box 2.
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ing, using a method called linkage group selection [28].
Subsequent sequencing of the region that was enriched
in resistant parasites identified two different mutations
in a gene encoding a deubiquitinating enzyme, pcubp-1,
suggesting that this gene could have resistance-
conferring alleles [16,27]. Although there have not been
many follow-up studies, the possible role of other genes
in the ubiquitin pathway in artemisinin resistance means
that pcubp-1 remains a viable candidate. In fact, variant
alleles of the pfubp-1 gene in P. falciparum (E1528D)
were significantly (P <0.001) more prevalent post-
treatment in Kenyan children with reduced responsive-
ness to ACTs than in those who responded better to
ACT [29].
In vitro evolution and genome scanning
While the original linkage-group selection studies were
underway, genome-analysis methods were becoming
more tractable in terms of both cost and sensitivity.
These methods allow researchers to find genes involved
in resistance to various small molecules that have anti-
malarial activity by simply analyzing the complete gen-
ome of the multiple resistant clones created by in vitro
evolution. Initially, tiling microarrays were designed tofind both newly emerged SNVs and copy number vari-
ants (CNVs) [30,31]; later, these variants were identified
by genome sequencing [32,33]. The approach was suc-
cessful in part because multiple independent resistant
lines were created, allowing identification of common
genes that were mutated in all independent resistant
lines. Although there was concern that it would be too
difficult, it soon became evident that resistance to dihy-
droartemsinin (DHA) could be evolved in P. falciparum
in the laboratory. Tucker and colleagues created several
lines that were resistant to artelinic acid and artemisinin
[34] and found potentially causative changes in candi-
date genes, including CNVs in pfmdr1. The results from
full genome sequencing were published only in thesis
format [35] and show that resistant lines acquired a
handful of nonsynonymous mutations, including one in
an uncharacterized protein on chromosome 13,
pf13_0238 (later renamed PF3D7_1343700), which
would later come to be known as kelch13 [36]. Other
groups created parasites that were 25 times more resist-
ant to DHA than the parental parasites [37]; these para-
sites showed further amplifications of a locus containing
pfmdr1. Although gene expression microarray analysis
was performed, the parasites were not subjected to
whole-genome sequencing (WGS).
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The search for markers that are associated with resistance
became more urgent, and in some ways more feasible,
when it became clear that parasites were developing resist-
ance to artemisinin in the field. In 2008, a letter to the edi-
tor of the New England Journal of Medicine publicly
documented the first clinical cases of suspected artemisinin
resistance, in a patient population from Western Cambodia
[38]. Noedl and colleagues [38] conducted clinical trials
with artesunate monotherapy in 94 adults presenting with
uncomplicated P. falciparum malaria in Battambang prov-
ince. This study, looking at the presence of parasites in the
blood after taking a standard dose, showed that artesunate
alone had failed to clear parasites in two adults. The treat-
ment of these two individuals was prolonged, but their in-
fections were ultimately cleared. There is an active debate
as to whether this situation should be best described as ar-
temisinin tolerance, to distinguish it from that in which
drug levels in the patient cannot be safely raised high
enough to kill the parasites effectively and to prevent recru-
descence [39-41]. For the sake of simplicity, the term ‘resist-
ant’ will be used in this review.
In 2009, a more comprehensive study compared pa-
tient responses to artesunate monotherapy in Western
Cambodia, Vietnam and north-western Thailand [17].
Measurements of parasite clearance times for 40 pa-
tients from each site demonstrated longer parasite clear-
ance times in Cambodia than in Thailand. Furthermore,
parasites taken from Cambodian patients into in vitro
cultures demonstrated a significant IC50 increase for
DHA, although not for chloroquine, mefloquine, or
artesunate. The authors of this study noted that artemi-
sinin administration in 2001 in Thailand was almost ex-
clusively in the form of ACTs, while in Cambodia, 78%
of artemisinin treatment had consisted of monother-
apies, which can drive parasites to acquire resistance
much more quickly. Although some sought to explain
the longer parasite clearance time observed in Western
Cambodia by an enrichment of possible human alleles
(such as the hemoglobin E (HbE) polymorphism) in this
region, studies showed that parasite genotype was more
predictive than human genotype [42]. Some small, but
statistically insignificant, differences in parasite-
clearance times were nevertheless associated with some
human alleles [42]. The human genotype theory became
less likely as further studies were carried out. In 2012,
resistance began to appear on the Thailand-Myanmar
border where increases in parasite clearance time were
quickly approaching those reported in western Cambodia
[43]. At the same time, a report of artemisinin-resistant par-
asites in Myanmar was also published [44].
The existence of parasites with heritable resistance
[42,45] spurred the design of parasite population genetic
studies that could be used to map genes involved inresistance. In the absence of patient phenotype data,
some groups sought simply to identify genomic regions
under selection using large collections of existing para-
sites. It had been known for many years that there is
linkage disequilibrium around genes involved with either
chloroquine [46] or pyrimethamine resistance [47], and
it was hypothesized that there might be genomic regions
in disequilibrium that would correlate with artemisinin
sensitivity.
In one study, 61 parasite lines were screened against the
NIH Chemical Genomics Center Pharmaceutical Collection
containing 2,816 compounds that are registered or ap-
proved for human or animal use. The parasite lines were
genotyped and genotypes were examined for association
with differential drug sensitivity to endoperoxides. Genes
associated with responses to ART included mal13p1.268 (a
Plasmodium conserved protein), pf11_0188 (a heat shock
protein 90), pfe0565w (a conserved Plasmodium protein),
pf08_0130 (a ribosomal-RNA-processing WD-repeat pro-
tein), pfa0655w (SURFIN), and pfi0355c (an adenosine
triphosphate-dependent heat shock protein) [48].
Mu and colleagues [49] subsequently genotyped 189
culture-adapted parasites collected from diverse loca-
tions, including 146 from Asia, using a custom-built
Affymetrix molecular inversion probe 3 K malaria panel
array with a coverage of approximately one single nu-
cleotide polymorphism (SNP) per 7 kb. Their genome-
wide scan for loci associated with responses to DHA,
utilizing only Asian parasites, revealed novel loci on
chromosome 1, 3 and 8 [49]. In another study with 45
cultured P. falciparum parasites from diverse geograph-
ical sources [50], some chromosomal regions (notably
on chromosome 4) were found to be associated with in-
creased sensitivity to DHA and artemisinin, but none of
the associations were strong enough to be significant or
worthy of follow-up. It should be noted that both of
these studies provided strong evidence of selection
around known resistance genes, such as pfcrt, pfdfhr,
and pfmdr1, indicating that the overall method was
working [49,50]. Although it is possible that artemisinin-
resistance alleles might not have been suitably repre-
sented in the starting parasite populations, it is also
possible that the standard IC50 assay that was used for
phenotyping was not sufficiently sensitive. Artemisinin
resistance is now considered easier to detect and quan-
tify in cell culture using a ring-stage assay [51] of syn-
chronized parasites (Figure 1).
These early studies clearly lacked both clinical phenotypic
data and parasite samples with demonstrated resistance. To
overcome this, studies were set up to recruit patients, to
measure the amount of time needed to clear parasites
after artemisinin monotherapy (compared with the stand-
ard ACT), and to obtain parasite material for genome
analysis from areas such as Cambodia, where genetically
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control areas. The first major study, published in 2012, ana-
lyzed 91 parasite samples from Cambodia, Thailand, and
Laos that were phenotyped for parasite clearance time [52].
The group utilized a custom Nimblegen genotyping array
scoring both SNVs at a density of 1 per 500 bp as well as
CNVs, with further fine-mapping using microsatellite ana-
lysis. The authors showed that although artemisinin resist-
ance was probably not the result of a single originating
event, either geographically or temporally, a clinical slow
parasite clearance rate was strongly associated with a select-
ive sweep on chromosome 13. Hypotheses about the actual
gene involved were not resolved, although a 35 kb region
on chromosome 13 (bases 1,759,466 to 1,794,766, Plas-
moDB 11.1) was highlighted as a probable marker of resist-
ance. Subsequent work by Ariey [36] would eventually
show that the window was slightly too narrow, potentially
because genotyping markers were too sparse in the region
or alternatively because a genotyping marker was in a poly-
morphic sequence tract, which could distort the boundaries
of a selective sweep.
Takala-Harrison and colleagues [53] genotyped para-
sites in 331 clinical infections from patients from Pailin,
Cambodia, Wang Pha, Thailand and Bangladesh that
had been phenotyped for parasite clearance time after
artesunate monotherapy. An Affymetrix SNP array was
used to analyze parasite genotypes at 8,079 positions.
Modeling significant association with parasite clearance
half-life, the time needed for parasitaemia to be reduced
by half during the log-linear phase of parasite clearance
[54], or parasite clearance time, four SNPs were identi-
fied on chromosomes 4, 10 and 13. Of these, two SNPs
were calculated to be ‘located within a top-ranked signa-
ture of recent positive selection’. Both of these SNPs
(MAL13-1718319 and MAL13-1719976) were found on
chromosome 13, within 2,000 bp of each other; one was
within pf3d7_1343400 (formerly mal13p1.216, located
between bases 1,714,443 to 1,719,255, PlasmoDB 11.1).
This study was not designed to identify exact alleles
causing resistance (as opposed to loci associated with
resistance), but the authors further emphasized the
importance of the 100-kb region on chromosome 13, al-
though narrowly missing the probable gene with causa-
tive alleles.
Miotto and colleagues [55] sought to refine the mapping
and identify possible causal SNPs in the locus under selec-
tion by genotyping 825 P. falciparum infections from 10 lo-
cations in West Africa and Southeast Asia. Infections were
phenotyped for parasite clearance time after artesunate
monotherapy in Southeast Asia and genotyped using short-
read high-throughput sequencing on an Illumina platform.
The authors showed that one resistant subpopulation of
parasites from Southeast Asia (KH2) had essentially a single
haplotype extending across half of chromosome 13, from1.4 Mb to 3.4 Mb, which is strong evidence of a recent se-
lective sweep. This group was able to postulate that the re-
gion was important, but even with genotyping at 86,158
coding SNPs, they were unable to perform further fine-
scale population mapping without further sexual recombin-
ation between resistant and sensitive parasites to break up
the interval.
Combined approaches
It was not until very recently that a candidate artemisinin-
resistance gene was identified with high confidence. In a re-
port published in January of 2014 [36], Ariey and colleagues
used a combination of next-generation WGS (approxi-
mately 500X) of an artemisinin-resistant line selected by
continuous exposure to artemisinin for five years in vitro
and population genetics studies. The genomic sequence
from their laboratory-evolved artemisinin-resistant isolate
was compared with that of an isogenic parent. After dis-
carding emerged variants in multigene families, synonym-
ous mutations, and alleles with mixed reads, Ariey and
colleagues were able to identify eight non-synonymous can-
didate mutations in seven genes that had emerged during
resistance selection. They retrospectively examined the
times at which the mutations appeared in their line and
concluded that a M476I coding change in PF3D7_1343700,
a Kelch propeller domain-containing protein (K13), arose
co-incident with the appearance of strong artemisinin re-
sistance in their in vitro population and was most likely
causative (Figure 1 and Box 3). Although it is too early to
know the exact function of K13 in P. falciparum, studies in
other organisms have sometimes shown a role in protein
turnover (Box 3). The gene, PF3D7_1343700 (bases
1,724,817 to 1,726,997, PlasmoDB 11.1) is notably very near
the regions that had been identified as under selection by
the population genetic studies [52,55]. To obtain further
support, Ariey and colleagues sequenced the regions
around the eight candidate SNPs in 49 culture-adapted iso-
lates from Southeast Asia that had artemisinin sensitivity
data associated with them, and showed that only mutations
in PF3D7_1343700 (including a C580Y change), were
strongly associated with survival in the ring-stage assay
(RSA) and with long parasite clearance half-life in patients,
although they did not find the in vitro-derived M476I mu-
tation in their samples. The authors analyzed the frequency
of mutations in this gene in parasite samples from regions
with and without resistance and found further association
between resistance and this gene.
Another recent and comprehensive study by Ashley and
colleagues [56] characterized parasite clearance half-life
under the administration of artesunate monotherapy at ten
sites, including seven spread throughout Southeast Asia.
The authors also obtained the full sequence of pfkelch13
using PCR amplification and Sanger sequencing (Figure 1).
The authors, members of the Tracking Resistance to
Box 3. Kelch-domain proteins
Kelch-domain proteins are found throughout different phyla. Their
name comes from the German word for chalice, and is derived
from the appearance of the eggs of a mutant Drosophila
melanogaster line first characterized by the developmental biologist
and Nobel laureate Christiane Nusselin-Volhard [78]. Their disruption
can give a wide variety of different phenotypes, although they are
often found in complexes that perform ubiquitinylation in which
the Kelch protein functions as the adaptor protein binding to the
substrate that will be ubiquitinylated and marked for protein
degradation. For example, in humans, the Kelch-like erythroid
cell-derived protein with CNC homology [ECH]-associated protein 1,
Keap1, which like Kelch13p contains a BTB dimerization domain,
represses the antioxidant transcriptional response by facilitating the
ubiquitinylation and proteosomal degradation of a key transcription
factor, the NRF2 (nuclear factor erythroid 2-related factor 2 (Nrf2))
transcription factor [79], in the absence of oxidative stress [80]. In
human hepatocytes, modulation of Keap1 activity also alters the cell
cycle, delaying S phase entry [81].
Notably, artemisinin treatment causes ring-stage parasites, which
are substantially less susceptible to the killing action of the
drug [67], to enter a dormant phase [34,82], and at least some
resistant parasites seem able to recover from dormancy after
treatment and begin growing again [82]. Some genetically resistant
parasites from Southeast Asia, where pfkelch13 mutations are
common, have an extended ring stage and longer cell cycle [83].
Figure 3 shows a hypothetical model based on existing data. In
the presence of artemisinin, free radicals are present that cause
a subset of ring-stage parasites to enter a transcriptionally or
epigenetically regulated dormant phase modulated by possible
nuclear proteins (transcription factors (TFs)) that respond to
oxidative stress. In most human infections, the red cells
containing these dormant parasites are eventually cleared with
the assistance of the immune system and the spleen (as human
malaria is not always fatal in the absence of chemotherapy),
resulting in a cure. Mutations in pfkelch13 might prime the
parasite to respond to oxidative stress while simultaneously
increasing the time spent in the less susceptible times of the
cell cycle. These responses would result in a higher proportion
of dormant parasites that have the potential to survive and
recrudesce. In the absence of pfkelch mutations, the TF could
be ubiquitinylated in the cytoplasm and degraded, a process
potentially mediated by PfKelch13p. A ubiquitin carboxy (UBC)
terminal hydrolase could be involved in recycling ubiquitin - its
disruption might also drive the putative TF to a de-ubiquitinylated
state. A role in ubiquitin-dependent protein turnover or regulation
could explain why rodent malaria parasites that are exposed to
artesunate acquire mutations in a gene encoding the deubiquitinat-
ing enzyme, pcubp1 (pf3d7_0104300 a ubiquitin carboxyl-terminal
hydrolase 1 in P. falciparum) [27]). Although this seems the most
plausible model, others are possible: for example, pfkelch13 also
encodes a weak CAF1 150 domain, named after a domain found in
chromatin assembly factor subunit 150 [80], the complex that
loads histones onto newly replicated DNA. Thus pfkelch13
could also directly impact gene silencing and transcriptional
regulation.
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clearance times in Indochina, but no significant resistance
in a single patient from India, or anywhere in Africa. They
found a strong association between mutations in pfkelch13
and the artemisinin-resistance phenotype. Although this
study involved assessments of parasite clearance in patients
treated with artemisinin-based monotherapy, followed by
standard combination therapy, treatment failure with arte-
misinin piperaquine ACTs have been reported in Cambodia
[7,57]. One bright spot is that mutations in pfkelch13 may
also come with a cost to parasite fitness, and might be lost
rapidly in populations in the absence of artemisinin
selection.
Genetic engineering
The propeller-domain mutations in pf3kelch13 were only
associated with resistance, although strongly, and were
not shown to be causal. A genome-modification method,
the CRISPR-Cas9 system, which was established for gen-
ome editing in other eukaryotes [58] and adapted to P.
falciparum [59,60], was used to show definitively that
one of the alleles and not some other second-site muta-
tion caused resistance. The C580Y change was engi-
neered into the Kelch propeller domain of pf3kelch13 in
the drug-sensitive NF54 background (of unknown ori-
gin). In vitro assays on two modified clones provided
evidence of an increase in ring-stage resistance, provid-
ing additional support for the role of this gene [60].
Studies to assess the effect of introducing or removing
the most prevalent pfkelch13 mutations from clinical iso-
lates are keenly awaited. These studies should firmly es-
tablish whether pfkelch13 mutations do indeed confer
resistance in clinical samples, although it is also possible
that there are other, as yet unidentified, determinants.
Future perspectives
One must keep in mind that the vast majority of malaria
infections occur in Sub-Saharan Africa, where ACTs still
appear to clear parasites quickly and where mutations in
the pfkelch13 have not yet appeared at elevated rates
[56]. Longitudinal studies have not shown increased fre-
quencies of mutations in pfkelch13 in Ugandan children
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Figure 3 Kelch structure, the position of mutations in the pfKelch13 gene, and a theoretical functional model. (a) Homology model of
PfKelch13p (amino acids 444 through 723) generated using SWISS-MODEL and the human Kelch-like protein 12 crystral structure (2vpj.1.A) as a
template. Two rotation views are shown. (b) Predicted domains and locations of mutations in pfkelch13 (PF3D7_1343700) identified either in vitro
[35,36] or in vivo [36,56]. Mutations in pink are in the Kelch domain modeled above while green ones are in the predicted regions with more
ambiguous function. Mutations mentioned in the text are specifically indicated. In addition to Kelch domains, PfKelch13p contains a BTB domain,
typically involved in dimerization. (c) Theoretical model of PfKelch function in artemisinin resistance. See Box 3 for details. TF, transcription factor.
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missing in Africa, African parasites have other pfkelch13
alleles [62]. If clinical trials measuring parasite clearance
time are used, there may be a problem with even quanti-
fying the amount of resistance in Africa, where partial
host immunity from repeated exposure may mask theloss of drug efficacy [63]. In fact, studies with Malian
children show that antimalarial immunity correlates
with fast artemisinin-induced parasite clearance [64]. In
addition, artemisinins are typically given as a combin-
ation in Africa, and while there are reports of late-stage
treatment failure after ACT use [7,57], there are not yet
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resulted from ACT resistance. Chloroquine resistance is be-
lieved to have arisen just a few times in Africa and to have
been imported from Asia in these cases [46]. Nevertheless,
given that artemisinin resistance can be evolved in a tissue
culture flask that contains many fewer parasites than a
chronically infected human, the chance of independent de
novo mutations emerging in Africa is high, especially as
there has been a 30-fold increase in ACT usage worldwide
(from 11 million courses to 331 courses) between 2006 and
2013 [2] as availability has increased. Furthermore, because
mutations found from in vitro selection are not the same
ones found in humans [37], there may be many ways to
create resistance. Indeed, evidence suggests that artemisinin
resistance has already emerged independently at least three
different times in Southeast Asia alone [55].
Along with clinical monotherapy testing and cellular
assays [51], the mutations in pfkelch13 can now be used
to study the spread of resistance and to identify zones
where alternative therapies should be used [65]. How-
ever, many questions remain for scientists and clinicians.
For example, are there other ways to create resistance
besides mutations in pfkelch13? The laboratory-derived
artemisinin-resistant lines created by Matthew Tucker
had mutations in genes other than pfkelch13, including
pff0275c (renamed PF3D7_0605600, a dinucleoside kinase)
[35]. Are any of these additional mutations in some of the
other chromosomal regions identified as under selection
in population studies [52,53,55,56]? With which proteins
does Pfkelch13p interact and would these also be resistant
determinants? Will the mutations that have been identi-
fied in pfkelch13 make parasites resistant against the
synthetic endoperoxides, such as OZ439 [66]. Given that
artemisinin has its greatest effect on trophozoite- and
schizont-stage parasites [67], are there other genes, such
as pffalcipain-2 [68], that may be found mutated in field
samples?
Studies of artemisinin resistance are already impacting
patient treatment. In parts of Southeast Asia, older ther-
apies are being reintroduced and patients are being ad-
mitted to hospitals so that their response can be
monitored. There are also calls for focused and intensive
plans to eliminate malaria from those regions were re-
sistance has been observed to keep resistance from
spreading [69]. While these measures may have an im-
pact, it may be that the world health community will
need to reduce reliance on this class of drugs. Luckily,
many predicted that artemisinins would eventually lose
their efficacy, and these predictions provided impetus to
initiate searches for new classes of antimalarials, some of
which are now in clinical trials.
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